Plasma Cell Neoplasm Clinical Trials
- PS-341 in Treating Patients With Refractory or Progressive Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00049478 - Active, not recruiting
refractory plasma cell neoplasm
- AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00022282 - Active, not recruiting
refractory plasma cell neoplasm
- Biological Therapy in Treating Patients With Multiple Myeloma That Has Recurred Following Bone Marrow Transplantation
ClinicalTrials.gov Identifier: NCT00003153 - Active, not recruiting
refractory plasma cell neoplasm
- Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
ClinicalTrials.gov Identifier: NCT00258245 - Active, not recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00049374 - Active, not recruiting
refractory plasma cell neoplasm
- Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00112723 - Recruiting
Leukemia; Lymphoma; plasma cell neoplasm
- Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia
ClinicalTrials.gov Identifier: NCT00003512 - Active, not recruiting
refractory plasma cell neoplasm; Waldenstrom's Macroglobulinemia
- High-Dose Melphalan, Total-Body Irradiation, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma in First Relapse
ClinicalTrials.gov Identifier: NCT00002630 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00004903 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Epoetin alfa in Treating Anemia in Patients With Solid Tumors
ClinicalTrials.gov Identifier: NCT00058331 - Active, not recruiting
adult solid tumor; Anemia; Leukemia; Lymphoma; plasma cell neoplasm
- Paricalcitol and Zoledronate in Treating Patients With Relapsed or Refractory Multiple Myeloma or Other Plasma Cell Disorders
ClinicalTrials.gov Identifier: NCT00258258 - Recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Epoetin alfa in Treating Cancer-Related Anemia in Patients With Non-Myeloid Cancer Who Are Not Currently Receiving Chemotherapy or Radiation Therapy
ClinicalTrials.gov Identifier: NCT00090935 - Active, not recruiting
adult solid tumor; Anemia; Leukemia; Lymphoma; plasma cell neoplasm
- Darbepoetin alfa Compared With Epoetin alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer
ClinicalTrials.gov Identifier: NCT00070382 - Active, not recruiting
adult solid tumor; Anemia; Leukemia; Lymphoma; plasma cell neoplasm
- Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00005792 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Brostallicin in Treating Patients With Recurrent or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00060203 - Active, not recruiting
stage III multiple myeloma; refractory plasma cell neoplasm
- Melphalan, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003954 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00006225 - Active, not recruiting
Breast Cancer; Leukemia; Lymphoma; Male Breast Cancer; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm
- Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00014508 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00044954 - Active, not recruiting
Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm
- Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer
ClinicalTrials.gov Identifier: NCT00248430 - Active, not recruiting
Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm
- Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003490 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
ClinicalTrials.gov Identifier: NCT00068523 - Active, not recruiting
chronic myeloproliferative disorders; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm
- CpG 7909 in Treating Patients Who Have Undergone Autologous Stem Cell Transplant
ClinicalTrials.gov Identifier: NCT00369291 - Recruiting
Germ Cell Tumor; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm
- Combination Chemotherapy Followed by Donor Bone Marrow Transplantation or Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer or Genetic Disorders
ClinicalTrials.gov Identifier: NCT00008307 - Active, not recruiting
childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; plasma cell neoplasm
- Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00004165 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis
- Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00296023 - Active, not recruiting
Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
- R115777 in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00021203 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction
ClinicalTrials.gov Identifier: NCT00054483 - Recruiting
adult non-Hodgkin's lymphoma; adult solid tumor; Multiple Myeloma; refractory plasma cell neoplasm
- Bortezomib Compared With Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00052260 - No longer recruiting
refractory plasma cell neoplasm
- Bryostatin 1 in Treating Patients With Relapsed Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00002907 - Completed
refractory plasma cell neoplasm
- Total-Body Irradiation With Or Without Fludarabine Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
ClinicalTrials.gov Identifier: NCT00075478 - Recruiting
childhood Hodgkin's lymphoma; childhood non-Hodgkin's lymphoma; Leukemia; Lymphoma; plasma cell neoplasm
- Darbepoetin alfa in Treating Anemia in Patients With Non-Myeloid Cancer Who Are Not Receiving Chemotherapy
ClinicalTrials.gov Identifier: NCT00098696 - Recruiting
adult solid tumor; Anemia; Leukemia; Lymphoma; plasma cell neoplasm
- Sorafenib in Treating Patients with Metastatic Or Unresectable Solid Tumors, Multiple Myeloma, Or Non-Hodgkin''s Lymphoma with Or Without Impaired Liver Or Kidney Function
ClinicalTrials.gov Identifier: NCT00118170 - Active, not recruiting
adult non-Hodgkin''s lymphoma; adult solid tumor; Multiple Myeloma; refractory plasma cell neoplasm
- Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms
ClinicalTrials.gov Identifier: NCT00082784 - Recruiting
adult non-Hodgkin's lymphoma; indolent or aggressive adult non-Hodgkin's lymphoma; refractory plasma cell neoplasm
- Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease
ClinicalTrials.gov Identifier: NCT00176475 - Recruiting
Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm
- Suramin in Treating Patients With Refractory or Relapsed Multiple Myeloma or Castleman's Disease
ClinicalTrials.gov Identifier: NCT00002652 - Completed
refractory plasma cell neoplasm
- Combination Chemotherapy With or Without Thalidomide in Treating Patients With Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00005834 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon alfa in Treating Patients With Advanced Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00006244 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00006890 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Chemotherapy, Holmium Ho 166 DOTMP, and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00045136 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- High-Dose Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Amyloidosis
ClinicalTrials.gov Identifier: NCT00002810 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; primary systemic amyloidosis
- Vaccine Therapy Plus Donor Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00020306 - Active, not recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Dexamethasone With or Without Oblimersen in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00017602 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Dexamethasone and Chemotherapy With or Without Plasma Exchange in Patients With Newly Diagnosed Multiple Myeloma and Acute Kidney Failure
ClinicalTrials.gov Identifier: NCT00416897 - Recruiting
Multiple Myeloma and Plasma Cell Neoplasm; Renal Failure
- FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00066638 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis
ClinicalTrials.gov Identifier: NCT00458822 - Recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- CI-994 in Treating Patients With Advanced Myeloma
ClinicalTrials.gov Identifier: NCT00005624 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Chemotherapy Plus Steroid Therapy in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003603 - Active, not recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Tandem Autologous Stem Cell Transplantation With or Without Maintenance Therapy After the Second Transplantation Compared With Autologous Stem Cell Transplantation Followed By Matched Sibling Allogeneic Stem Cell Transplantation in Patients With Stage II
ClinicalTrials.gov Identifier: NCT00075829 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00124579 - Active, not recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00046852 - Active, not recruiting
Infection; refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00004158 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; stage I multiple myeloma; refractory plasma cell neoplasm
- Arsenic Trioxide in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00017433 - Active, not recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Stem Cell Transplantation in Treating Patients With Previously-Treated Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00054353 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation
ClinicalTrials.gov Identifier: NCT00003538 - Active, not recruiting
Leukemia; Lymphoma; Plasma Cell Neoplasm; Aplastic Anemia; Solid Tumor; Graft Versus Host Disease
- Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00028600 - Recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
ClinicalTrials.gov Identifier: NCT00453206 - Recruiting
Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
- Fenretinide in Treating Patients With Refractory or Relapsed Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00104923 - Recruiting
Hodgkin's lymphoma; acute leukemia; chronic leukemia; chronic myeloproliferative disorders; Non-Hodgkin's Lymphoma; plasma cell neoplasm
- Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
ClinicalTrials.gov Identifier: NCT00423826 - Recruiting
Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Secondary Myelofibrosis
- Combination Chemotherapy With or Without PSC 833 in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00002878 - Completed
refractory plasma cell neoplasm
- SU5416 in Treating Patients With Refractory or Relapsed Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00006013 - Completed
refractory plasma cell neoplasm
- Palifermin in Reducing or Preventing Mucositis in Patients Who Are Receiving Radiation Therapy and Chemotherapy Followed by an Autologous Stem Cell Transplant for Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00126529 - Recruiting
Drug Toxicity; Leukemia; Lymphoma; oral complications of cancer and cancer therapy; plasma cell neoplasm; radiation toxicity
- Intensity-Modulated Radiation Therapy, Fludarabine, and Melphalan Followed by a Donor Stem Cell Transplant in Treating Patients With Hematological Cancer
ClinicalTrials.gov Identifier: NCT00544466 - Recruiting
Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
- Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00006021 - Completed
refractory plasma cell neoplasm
- Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00017069 - Active, not recruiting
refractory plasma cell neoplasm; stage II multiple myeloma; stage III multiple myeloma
- Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
ClinicalTrials.gov Identifier: NCT00448201 - Recruiting
Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
- Fludarabine, Busulfan, and Alemtuzumab Followed By Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases
ClinicalTrials.gov Identifier: NCT00448357 - Recruiting
Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
- Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
ClinicalTrials.gov Identifier: NCT00534118 - Recruiting
Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
- Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation
ClinicalTrials.gov Identifier: NCT00064311 - Active, not recruiting
Breast Cancer; Chronic Myeloproliferative Disorders; Gestational Trophoblastic Tumor; Infection; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Neuroblastoma; Ovarian Cancer; Testicular Germ Cell Tumor
- Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
ClinicalTrials.gov Identifier: NCT00564889 - Recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Sorafenib in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00253578 - Recruiting
Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma; Refractory Plasma Cell Neoplasm
- Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00124605 - Active, not recruiting
unspecified adult solid tumor, protocol specific; refractory plasma cell neoplasm; stage III multiple myeloma; stage II multiple myeloma
- T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
ClinicalTrials.gov Identifier: NCT00080925 - Recruiting
chronic myeloproliferative disorders; Leukemia; Lymphoma; myelodysplastic and myeloproliferative diseases; plasma cell neoplasm
- Antineoplaston Therapy in Treating Patients With Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00003511 - Recruiting
refractory plasma cell neoplasm; stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma
- Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00134004 - Recruiting
childhood Hodgkin''s lymphoma; childhood non-Hodgkin''s lymphoma; chronic myeloproliferative disorders; Leukemia; Lymphoma; plasma cell neoplasm
- Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00445692 - Recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant
ClinicalTrials.gov Identifier: NCT00288028 - Recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00499577 - Recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Prevention of Graft-Versus-Host Disease Following Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00019851 - Active, not recruiting
Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
- Bryostatin 1 Plus Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia or Relapsed Indolent Non-Hodgkin's Lymphoma
ClinicalTrials.gov Identifier: NCT00005580 - Completed
Leukemia; Lymphoma; plasma cell neoplasm
- Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00085345 - Recruiting
stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Cyclophosphamide and Melphalan Followed By an Autologous Stem Cell Transplant, Dexamethasone, and Thalidomide in Treating Patients With Previously Treated Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00293306 - Recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00316940 - Active, not recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction
ClinicalTrials.gov Identifier: NCT00547365 - Recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Chemotherapy and Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Disease or Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00003838 - Recruiting
Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; ...
- Gene Therapy for the Treatment of Brain Tumors
ClinicalTrials.gov Identifier: NCT00001328 - Active, not recruiting
Brain Neoplasm; Neoplasm Metastasis
- Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00317811 - Active, not recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone a Previous Autologous or Syngeneic Bone Marrow or Stem Cell Transplant for Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00182663 - Recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Combination Chemotherapy, Tacrolimus, and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant For Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00134017 - Recruiting
childhood Hodgkin''s lymphoma; childhood non-Hodgkin''s lymphoma; chronic myeloproliferative disorders; Leukemia; Lymphoma; plasma cell neoplasm
- Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
ClinicalTrials.gov Identifier: NCT00544115 - Active, not recruiting
Chronic Myeloproliferative Disorders; Graft Versus Host Disease; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Precancerous/Nonmalignant Condition
- Melphalan and Radiation Therapy Followed By Dexamethasone and Thalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00112827 - Recruiting
stage I multiple myeloma; stage II multiple myeloma; stage III multiple myeloma; refractory plasma cell neoplasm
- Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00477815 - Recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Low-Dose Melphalan and Dexamethasone Compared With High-Dose Melphalan Followed By Autologous Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis
ClinicalTrials.gov Identifier: NCT00477971 - Recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00227682 - Active, not recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00281879 - Recruiting
Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases; Unusual Cancers of Childhood
- Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer
ClinicalTrials.gov Identifier: NCT00255749 - Active, not recruiting
Anemia; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Unspecified Adult Solid Tumor, Protocol Specific
- Melphalan and Palifermin in Treating Patients Undergoing An Autologous Peripheral Stem Cell Transplant for Stage II or III Multiple Myeloma
ClinicalTrials.gov Identifier: NCT00482846 - Recruiting
Drug Toxicity; Mucositis; Multiple Myeloma and Plasma Cell Neoplasm
- Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease
ClinicalTrials.gov Identifier: NCT00520767 - Recruiting
Multiple Myeloma and Plasma Cell Neoplasm
- Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer
ClinicalTrials.gov Identifier: NCT00281775 - Recruiting
Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
- Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia
ClinicalTrials.gov Identifier: NCT00295997 - Active, not recruiting
Chronic Myeloproliferative Disorders; Kidney Cancer; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]
| 
Not Signed In - 
email this page
print this page
bookmark this page
feedback on this page
